Understanding LAG-3 Signaling.
LAG-3
cancer signaling
immune checkpoint
immunotherapy
targeted therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 May 2021
17 May 2021
Historique:
received:
22
04
2021
revised:
12
05
2021
accepted:
13
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ago as an inhibitory immune checkpoint molecule comparable to PD-1 and CTLA-4 and a potential target for enhancing anti-cancer immune responses. LAG-3 is the third inhibitory receptor to be exploited in human anti-cancer immunotherapies, and it is considered a potential next-generation cancer immunotherapy target in human therapy, right next to PD-1 and CTLA-4. Unlike PD-1 and CTLA-4, the exact mechanisms of action of LAG-3 and its relationship with other immune checkpoint molecules remain poorly understood. This is partly caused by the presence of non-conventional signaling motifs in its intracellular domain that are different from other conventional immunoregulatory signaling motifs but with similar inhibitory activities. Here we summarize the current understanding of LAG-3 signaling and its role in LAG-3 functions, from its mechanisms of action to clinical applications.
Identifiants
pubmed: 34067904
pii: ijms22105282
doi: 10.3390/ijms22105282
pmc: PMC8156499
pii:
doi:
Substances chimiques
Antigens, CD
0
Receptors, Immunologic
0
Lymphocyte Activation Gene 3 Protein
0
Lag3 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundación Científica Asociación Española Contra el Cáncer
ID : PROYE16001ESCO
Organisme : Instituto de Salud Carlos III
ID : FIS PI17/02119
Organisme : Instituto de Salud Carlos III
ID : FIS PI20/00010
Organisme : Departamento de Salud, Gobierno de Navarra
ID : BMED 050-2019
Organisme : Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra
ID : AGATA, Ref 0011-1411-2020-000013
Organisme : Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra
ID : LINTERNA, Ref. 0011-1411-2020-000033
Organisme : Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra
ID : DESCARTHES, 0011-1411-2019-000058
Organisme : Horizon 2020 Framework Programme
ID : ISOLDA; ID: 848166
Organisme : Instituto de Salud Carlos III
ID : TRANSPOCART ICI19/00069
Organisme : Instituto de Salud Carlos III
ID : COV20/00000
Références
Nat Rev Clin Oncol. 2017 Jun;14(6):381-390
pubmed: 28290490
Leukemia. 2017 Mar;31(3):738-743
pubmed: 27840427
Front Immunol. 2018 Dec 17;9:2922
pubmed: 30619285
J Immunol. 2009 Jun 1;182(11):6659-69
pubmed: 19454660
EMBO Mol Med. 2020 Sep 7;12(9):e12706
pubmed: 32648370
J Immunol. 2011 Oct 1;187(7):3493-8
pubmed: 21873518
Sci Rep. 2018 Oct 2;8(1):14600
pubmed: 30279468
J Virol. 2019 Aug 28;93(18):
pubmed: 31217250
Braz J Med Biol Res. 2017 Mar 23;50(4):e5356
pubmed: 28355349
Am J Pathol. 2015 Mar;185(3):820-33
pubmed: 25549835
Proc Natl Acad Sci U S A. 1997 May 27;94(11):5744-9
pubmed: 9159144
Front Pharmacol. 2020 Apr 07;11:441
pubmed: 32317979
Anal Biochem. 1996 Oct 1;241(1):93-102
pubmed: 8921170
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
Nature. 2018 Jun;558(7710):454-459
pubmed: 29899446
Diabetes. 2012 Jul;61(7):1760-8
pubmed: 22586584
J Immunol. 1999 Mar 1;162(5):2748-53
pubmed: 10072520
Cancers (Basel). 2020 Aug 14;12(8):
pubmed: 32823814
JAMA Oncol. 2017 Jul 1;3(7):974-978
pubmed: 28334399
Oncotarget. 2017 May 29;8(37):61425-61439
pubmed: 28977875
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
J Exp Med. 2017 Feb;214(2):381-400
pubmed: 28115575
Genes Immun. 2005 Mar;6(2):145-52
pubmed: 15674389
Eur J Immunol. 2001 Oct;31(10):2885-91
pubmed: 11592063
Mucosal Immunol. 2016 Jan;9(1):137-45
pubmed: 26013006
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13974-9
pubmed: 19666526
Nucleic Acids Res. 2019 Jan 8;47(D1):D745-D751
pubmed: 30407521
Eur J Immunol. 1995 Sep;25(9):2718-21
pubmed: 7589152
Eur J Immunol. 1994 Dec;24(12):3216-21
pubmed: 7805750
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
J Exp Med. 1992 Aug 1;176(2):327-37
pubmed: 1380059
J Immunol. 2014 Sep 15;193(6):3101-12
pubmed: 25108024
Clin Cancer Res. 2019 Aug 1;25(15):4663-4673
pubmed: 31053602
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Biomed Res Int. 2021 Jan 2;2021:6576210
pubmed: 33490273
FASEB J. 1996 May;10(7):769-76
pubmed: 8635694
Clin Epigenetics. 2020 Dec 9;12(1):188
pubmed: 33298174
Immunol Lett. 2013 Feb;150(1-2):116-22
pubmed: 23261718
Front Immunol. 2020 Jul 14;11:1469
pubmed: 32760400
Immunology. 2005 Jun;115(2):170-8
pubmed: 15885122
Transplantation. 2007 Dec 15;84(11):1500-6
pubmed: 18091527
Science. 2016 Sep 30;353(6307):
pubmed: 27708076
J Immunol. 1998 Oct 15;161(8):4058-65
pubmed: 9780176
Immunogenetics. 1998 Jul;48(2):116-24
pubmed: 9634475
Eur J Immunol. 1996 May;26(5):1180-6
pubmed: 8647185
J Allergy Clin Immunol. 2018 Nov;142(5):1537-1547.e8
pubmed: 29369775
JCI Insight. 2018 Jul 12;3(13):
pubmed: 29997292
Oncotarget. 2017 Jun 20;8(25):41011-41020
pubmed: 28487502
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
J Immunother Cancer. 2019 Feb 6;7(1):33
pubmed: 30728070
Immunity. 2004 Oct;21(4):503-13
pubmed: 15485628
Int Immunol. 2010 Jan;22(1):13-23
pubmed: 19880580
J Immunol. 2010 Jun 1;184(11):6545-51
pubmed: 20421648
JCI Insight. 2016 Oct 20;1(17):e88628
pubmed: 27777974
Cancer Biol Med. 2020 Nov 15;17(4):923-936
pubmed: 33299644
Aging (Albany NY). 2020 Dec 19;12(24):26095-26120
pubmed: 33401247
J Immunother Cancer. 2015 Jan 20;3(1):2
pubmed: 25614821
Biology (Basel). 2020 Apr 23;9(4):
pubmed: 32340360
J Clin Oncol. 2011 Dec 20;29(36):4828-36
pubmed: 22042955
J Breast Cancer. 2018 Jun;21(2):124-133
pubmed: 29963107
Haematologica. 2017 May;102(5):874-882
pubmed: 28154084
Eur J Immunol. 1997 Sep;27(9):2239-44
pubmed: 9341765
Oncotarget. 2015 Sep 29;6(29):27359-77
pubmed: 26318293
J Clin Invest. 2007 Nov;117(11):3383-92
pubmed: 17932562
Oncoimmunology. 2016 Sep 2;5(10):e1221555
pubmed: 27853645
Nat Rev Clin Oncol. 2017 Nov;14(11):655-668
pubmed: 28653677
J Immunol. 2004 Dec 1;173(11):6806-12
pubmed: 15557174
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986912
Clin Epigenetics. 2018 Mar 5;10:32
pubmed: 29527240
Int J Mol Sci. 2020 Dec 31;22(1):
pubmed: 33396515
Cancer Res. 2015 Sep 15;75(18):3747-59
pubmed: 26183926
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
J Immunol. 2011 May 1;186(9):5173-83
pubmed: 21441454
Blood. 2006 Oct 1;108(7):2280-9
pubmed: 16757686
Oncotarget. 2015 Mar 10;6(7):4936-52
pubmed: 25669973
Med Oncol. 2014 Aug;31(8):82
pubmed: 25034363
Immunity. 2018 Aug 21;49(2):342-352.e5
pubmed: 30097293
Cancer Immunol Res. 2015 Apr;3(4):412-23
pubmed: 25691328
EMBO J. 2007 Jan 24;26(2):494-504
pubmed: 17245433
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32234847
Clin Lung Cancer. 2018 May;19(3):249-259.e2
pubmed: 29396238
Front Oncol. 2019 Oct 15;9:1040
pubmed: 31681578
Nat Med. 2013 Jun;19(6):739-46
pubmed: 23624599
Oncotarget. 2017 Sep 21;8(52):89722-89735
pubmed: 29163783
J Biol Chem. 2019 Apr 12;294(15):6017-6026
pubmed: 30760527
Ann Oncol. 2017 Dec 1;28(12):2977-2984
pubmed: 29045526
Front Immunol. 2020 Nov 30;11:586907
pubmed: 33329566
J Immunol. 2002 Apr 15;168(8):3874-80
pubmed: 11937541
Immunity. 2018 Jul 17;49(1):120-133.e9
pubmed: 30005826
J Neuroinflammation. 2019 Dec 17;16(1):270
pubmed: 31847878
Immunity. 2016 May 17;44(5):989-1004
pubmed: 27192565
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
J Cancer Res Clin Oncol. 2018 Jun;144(6):1005-1014
pubmed: 29520442
J Cancer. 2018 Oct 20;9(22):4287-4293
pubmed: 30519331
Immunogenetics. 1994;39(3):213-7
pubmed: 7506235
J Immunol. 2004 May 1;172(9):5450-5
pubmed: 15100286
Front Immunol. 2018 Feb 27;9:385
pubmed: 29535740
Front Immunol. 2020 Dec 17;11:590618
pubmed: 33391264
J Crohns Colitis. 2020 Oct 5;14(10):1446-1461
pubmed: 32179884
Oncotarget. 2017 Feb 28;8(9):15242-15251
pubmed: 28146425
Curr Atheroscler Rep. 2021 Jan 5;23(1):5
pubmed: 33398433
PLoS Pathog. 2019 Jan 17;15(1):e1007429
pubmed: 30653605
EMBO Mol Med. 2019 Jul;11(7):e10293
pubmed: 31273938
J Immunol. 2002 Nov 15;169(10):5392-5
pubmed: 12421911
Yonago Acta Med. 2015 Mar;58(1):39-44
pubmed: 26190896
Immunol Lett. 1998 Apr;61(2-3):109-12
pubmed: 9657262
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Ann Oncol. 2018 Jan 1;29(1):71-83
pubmed: 29069302
Breast Cancer Res. 2021 Jan 7;23(1):4
pubmed: 33413541
Hum Immunol. 2018 Jul;79(7):564-570
pubmed: 29729899
Nat Commun. 2014 Sep 03;5:4741
pubmed: 25182274
Oncoimmunology. 2016 Oct 7;5(11):e1239005
pubmed: 27999760
J Immunol. 2005 Jan 15;174(2):688-95
pubmed: 15634887
Eur J Immunol. 2003 Apr;33(4):970-9
pubmed: 12672063
Eur J Immunol. 2002 Aug;32(8):2255-63
pubmed: 12209638
Eur J Immunol. 2005 Jul;35(7):2081-8
pubmed: 15971272
Microbiol Immunol. 2016 Feb;60(2):121-31
pubmed: 26696540
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
Front Immunol. 2016 Sep 14;7:355
pubmed: 27683580
PLoS One. 2014 Jul 15;9(7):e102331
pubmed: 25025430